RU2006140374A - Лечение нарушений - Google Patents

Лечение нарушений Download PDF

Info

Publication number
RU2006140374A
RU2006140374A RU2006140374/14A RU2006140374A RU2006140374A RU 2006140374 A RU2006140374 A RU 2006140374A RU 2006140374/14 A RU2006140374/14 A RU 2006140374/14A RU 2006140374 A RU2006140374 A RU 2006140374A RU 2006140374 A RU2006140374 A RU 2006140374A
Authority
RU
Russia
Prior art keywords
antibody
mammal
dose
administering
agent
Prior art date
Application number
RU2006140374/14A
Other languages
English (en)
Inventor
Пол Дж. БРУНЕТТА (US)
Пол Дж. БРУНЕТТА
Кэтрин Л. СЬЮЭЛЛ (US)
Кэтрин Л. СЬЮЭЛЛ
Original Assignee
Дженентек, Инк. (Us)
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженентек, Инк. (Us), Дженентек, Инк. filed Critical Дженентек, Инк. (Us)
Publication of RU2006140374A publication Critical patent/RU2006140374A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Claims (21)

1. Способ лечения полихондрита или множественного мононеврита у млекопитающего, включающий введение млекопитающему эффективного количества антитела, которое связывается с CD20.
2. Способ по п.1, в котором антитело не конъюгировано с другой молекулой.
3. Способ по п.1, в котором антитело конъюгировано с другой молекулой.
4. Способ по п.3, в котором другая молекула представляет собой цитотоксическое средство.
5. Способ по п.4, в котором цитотоксическое средство представляет собой радиоактивное соединение.
6. Способ по п. 4 или 5, в котором цитотоксическое средство содержит Y2B8 или 131I-B1.
7. Способ по п.1, в котором антитело содержит ритуксимаб.
8. Способ по п.1, в котором антитело содержит гуманизированный 2H7.
9. Способ по п.1, включающий введение млекопитающему дозы от приблизительно 20 мг/м2 до приблизительно 250 мг/м2 антитела.
10. Способ по п.9, в котором доза составляет от приблизительно 50 мг/м2 до приблизительно 200 мг/м2.
11. Способ по п.1, включающий введение начальной дозы антитела с последующим введением последующей дозы, причем доза в мг/м2 антитела в последующей дозе превышает дозу в мг/м2 антитела в начальной дозе.
12. Способ по п.1, в котором млекопитающее является человеком.
13. Способ по п.1, в котором антитело вводят внутривенно.
14. Способ по п.1, в котором антитело вводят подкожно.
15. Способ по п.1, дополнительно включающий введение млекопитающему эффективного количества иммуносупрессивного средства, болеутоляющего средства или химиотерапевтического средства.
16. Способ по п.1, в котором лечат полихондрит.
17. Способ по п.16, дополнительно включающий введение млекопитающему эффективного количества нестероидного противовоспалительного лекарственного средства, стероида, метотрексата, циклофосфамида, дапсона, азатиоприна, пеницилламина или циклоспорина.
18. Способ по п.1, в котором лечат множественный мононеврит.
19. Способ по п.18, дополнительно включающий введение млекопитающему эффективного количества болеутоляющего средства, стероида, метотрексата, циклофосфамида, плазмафереза, внутривенного иммуноглобулина, циклоспорина или мофетилмикофенолята.
20. Изделие, включающее контейнер и содержащуюся в нем композицию, причем композиция содержит антитело, которое связывается с CD20, и дополнительно включающее вкладыш с инструкцией для пользователя композиции по лечению полихондрита или множественного мононеврита у млекопитающего.
21. Изделие по п.20, дополнительно включающее контейнер, содержащий средство, отличное от антитела, для лечения и дополнительно содержащее инструкцию по лечению млекопитающего с использованием такого средства.
RU2006140374/14A 2004-04-16 2005-04-15 Лечение нарушений RU2006140374A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56322704P 2004-04-16 2004-04-16
US60/563,227 2004-04-16
US56509804P 2004-04-22 2004-04-22
US60/565,098 2004-04-22

Publications (1)

Publication Number Publication Date
RU2006140374A true RU2006140374A (ru) 2008-05-27

Family

ID=35207581

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006140374/14A RU2006140374A (ru) 2004-04-16 2005-04-15 Лечение нарушений

Country Status (12)

Country Link
US (2) US20060002930A1 (ru)
EP (1) EP1742660A2 (ru)
JP (1) JP2007532680A (ru)
AR (1) AR049021A1 (ru)
AU (1) AU2005247303A1 (ru)
BR (1) BRPI0509412A (ru)
CA (1) CA2562243A1 (ru)
IL (1) IL178553A0 (ru)
NO (1) NO20065252L (ru)
RU (1) RU2006140374A (ru)
TW (1) TW200603828A (ru)
WO (1) WO2005115453A2 (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU777970C (en) * 1999-05-07 2006-08-17 F. Hoffman-La Roche Ag Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
CA2422076A1 (en) * 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
TR201809892T4 (tr) * 2003-11-05 2018-07-23 Roche Glycart Ag Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller.
WO2006031370A2 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
EP1957082B1 (en) * 2005-12-02 2012-04-11 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs for treating immune disorders
KR20080079301A (ko) * 2005-12-09 2008-08-29 시애틀 지네틱스, 인크. Ｃｄ４０ 결합제를 이용하는 방법
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2008034076A2 (en) * 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2008034074A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
WO2008034071A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Method of identifying patients suitable for high-dose cyclophosphamide treatment
PL2840090T3 (pl) * 2007-10-30 2018-07-31 Genentech, Inc. Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej
US9026372B2 (en) * 2007-11-21 2015-05-05 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
WO2009067699A2 (en) * 2007-11-21 2009-05-28 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for an oxazaphosphorine drug regimen
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
WO2010138184A2 (en) * 2009-05-27 2010-12-02 Synageva Biopharma Corp. Avian derived antibodies
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
AU2010311567B2 (en) 2009-10-26 2015-03-26 Chugai Seiyaku Kabushiki Kaisha Method for the production of a glycosylated immunoglobulin
JP6012473B2 (ja) * 2010-01-11 2016-10-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃｄ２００抗体を用いたヒトの処置における免疫調節効果のバイオマーカー
MX341687B (es) 2010-02-10 2016-08-30 Immunogen Inc "anticuerpos cd20 y su utilización".
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US69545A (en) * 1867-10-08 curtis
US25764A (en) * 1859-10-11 Improvement in cultivators
US103971A (en) * 1870-06-07 Improvement in mechanical movement
US6404A (en) * 1849-05-01 shaw and ezra gould
US197255A (en) * 1877-11-20 Improvement in receivers and stench-traps for street-sewers
US197256A (en) * 1877-11-20 Improvement in saw-handles
US26801A (en) * 1860-01-10 peters
US18041A (en) * 1857-08-25 Xwashing-machine
US12665A (en) * 1855-04-10 Improvement sssi steam-boilers
US4587A (en) * 1846-06-20 Machine for lasting shoes and boots
US219433A (en) * 1879-09-09 Improvement in grain-binders
US88664A (en) * 1869-04-06 Improved device tor mowing- away hat
US219818A (en) * 1879-09-23 Improvement in evaporating-pans
US21781A (en) * 1858-10-12 Improved method o f lighting street-lamps by electricity
US82172A (en) * 1868-09-15 Frank stanley
US133930A (en) * 1872-12-17 Improvement in toy spring-guns
US136719A (en) * 1873-03-11 Improvement in travelers for spinning-rings
US9444A (en) * 1852-12-07 Hot-air furnace
US128468A (en) * 1872-07-02 Improvement in transferring the natural grain of wood
US41847A (en) * 1864-03-08 Improved washing-machine
US58029A (en) * 1866-09-11 Improved window-shade fastening
US185796A (en) * 1876-12-26 Improvement in chairs
US180292A (en) * 1876-07-25 Improvement in folding chairs
US9427A (en) * 1852-11-23 Whifeletree
US147885A (en) * 1874-02-24 Improvement in the manufacture of halters and bridles
US157108A (en) * 1874-11-24 Improvement in lubricating compounds
US93621A (en) * 1869-08-10 Improvement in wagon s
US965963A (en) * 1910-03-10 1910-08-02 Harry E Blanchard Burner for fuel-oils.
US1156066A (en) * 1915-06-18 1915-10-12 John W Dupuy Stove.
IL47062A (en) * 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4665077A (en) * 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5576195A (en) * 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US5567610A (en) * 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US6893625B1 (en) * 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) * 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
IL85746A (en) * 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
US4861579A (en) * 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) * 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) * 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DK0590058T3 (da) * 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5587458A (en) * 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
CA2128862C (en) * 1992-02-11 2008-05-20 Jonathan G. Seidman Homogenotization of gene-targeting events
US5573905A (en) * 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ATE196606T1 (de) * 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
JP3194680B2 (ja) * 1994-12-15 2001-07-30 三菱電機株式会社 内燃機関の失火検出装置
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6368596B1 (en) * 1997-07-08 2002-04-09 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) * 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
HU228180B1 (hu) * 1998-08-11 2013-01-28 Biogen Idec Inc Anti-CD20-ellenanyag alkalmazása B-sejtes limfómák kombinációs terápiájára
US6224866B1 (en) * 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
DE19930748C2 (de) * 1999-07-02 2001-05-17 Infineon Technologies Ag Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip
AU2002339845B2 (en) * 2001-08-03 2009-03-26 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CA2476166C (en) * 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
AU2003294210A1 (en) * 2002-07-31 2004-05-04 Seattle Genetics, Inc Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
US20040032828A1 (en) * 2002-08-16 2004-02-19 Cellglide Technologies Corp. Service management in cellular networks
ES2744275T3 (es) * 2002-10-17 2020-02-24 Genmab As Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple
US20040202658A1 (en) * 2003-04-09 2004-10-14 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to TNF-alpha inhibitor

Also Published As

Publication number Publication date
US20060002930A1 (en) 2006-01-05
US20070031331A1 (en) 2007-02-08
EP1742660A2 (en) 2007-01-17
BRPI0509412A (pt) 2007-09-04
JP2007532680A (ja) 2007-11-15
WO2005115453A2 (en) 2005-12-08
AU2005247303A1 (en) 2005-12-08
AR049021A1 (es) 2006-06-21
NO20065252L (no) 2007-01-15
WO2005115453A3 (en) 2006-03-16
CA2562243A1 (en) 2005-12-08
TW200603828A (en) 2006-02-01
IL178553A0 (en) 2007-02-11

Similar Documents

Publication Publication Date Title
RU2006140374A (ru) Лечение нарушений
RU2006147253A (ru) Способ лечения рассеянного склероза
Muntean et al. Immunosuppression in kidney transplantation
Levine Rituximab in the treatment of dermatomyositis: an open‐label pilot study
AU2011340472B2 (en) Antitumor combinations containing antibodies recognizing specifically CD38 and bortezomib
JP2008515890A5 (ru)
EP3442584B1 (en) Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
Dalakas Inflammatory myopathies: management of steroid resistance
JP2018522850A5 (ru)
JP2008501712A5 (ru)
JP2008540447A5 (ru)
HRP20150143T1 (hr) Imunokonjugati koji ciljaju na cd138 i njihova upotreba
US20200002428A1 (en) Treatment of c1013g/cxcr4-associated waldenstrom's macroglobulinemia with an anti-cxcr4 antibody
CA2744996A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and vincristine
DeNardo et al. Human antiglobulin response to foreign antibodies: therapeutic benefit?
JP2022177142A5 (ru)
RU2007134368A (ru) Способы лечения лимфом с использованием сочетания химиотерапевтического средства и il-2, и, не обязательно, антител анти-cd20
DE05075555T1 (de) Immuntherapie von Autoimmunerkrankungen durch die Verwendung von B-Zell-spezifischen Antikörpern
JP2020510671A5 (ru)
Iodice et al. Immunotherapy for autoimmune autonomic ganglionopathy
EP2849783A1 (en) Combination of cd37 antibodies with further agents
JP2021525735A (ja) 抗ｃｄ３７免疫コンジュゲート投薬レジメン
Sadaka et al. Management of antibody-mediated rejection in transplantation
JP2019508433A5 (ru)
WO2013160396A1 (en) Combination of cd37 antibodies with bendamustine

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20080528